When “better” isn’t good enough under Art. 84 EPC

​
George James
​
September 18, 2025

In the recent Decision T 2387/22, the Board's key message was: if you define an invention by a "relative improvement" of a known technical effect, the improvement must be expressed in "objectively verifiable" terms. Vague language like "stronger" or "fewer", unsurprisingly, won't cut it.

In this case, claim 1 of ARs 9 to 11 defined the use of a particular pigment in a flexographic ink formulation for providing: "fewer print defects, higher hiding and stronger colour and allowing a lower volume anilox".


The Board found these terms unclear because they lacked measurable parameters. Applying the above principle, it held that such wording fails Art. 84 EPC, especially when the prior art is close.
One noteworthy quote for opponents challenging ARs: "Where, as in the present case, the prior art is technically close to the claimed subject-matter, the clarity of the distinguishing features becomes all the more critical, since such proximity makes it readily apparent how vague or diffuse definitions may give rise to legal uncertainty in the assessment of patentability."


The Main Request fell for lack of inventive step, but the clarity issues around ARs 9 to 11 earned this decision a "C" distribution.

Recent Case Reports

Bringing enforcement proceedings while an appeal is still pending risks liability for defendant’s costs
24 September 2026
The Court of Appeal held that setting aside a first-instance decision granting relief subject to recurring penalties generally has retroactive effect. Any penalty fees already paid will be refunded by the Court. The value of proceedings is determined by the interest of the party that brought the action. This is not changed as a result of an appeal. A claimant bringing enforcement proceedings while an appeal is still pending does so at its own risk and may be liable for the defendant’s costs related to the enforcement proceedings.‍
Unsigned Appeal Rejected as Inadmissible
24 September 2026
The Court of Appeal held that a statement of appeal that is not electronically signed is not validly lodged under Rule 4.1 RoP, and that this defect cannot be cured after expiry of the non-extendable appeal period. The appeal was therefore rejected as inadmissible, and a late application for re-establishment of rights was itself held to be out of time.
Scripps mRNA reengineering patent found invalid and not infringed by Comirnaty
08 September 2026
The Local Division Munich invalidated Promosome's licensed mRNA patent over Scripps' codon-optimisation method, then found BioNTech's Comirnaty vaccine would not have infringed the claims even had they been valid.